#BEGIN_DRUGCARD DB01926

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C36H51FeN5O12

# Chemical_IUPAC_Name:
(8E)-9-[(1R,12R,15S,18S,20S,22R,30S,31S)-20-hydroxy-18-methyl-13,16,37-trioxo-2,10,17,28,29,36-hexaoxa-14,21,27,31,38-pentaaza-1-ferrahexacyclo[13.13.7.1^{1,31}.1^{9,12}.1^{22,27}.0^{3,8}]octatriaconta-3,5,7,9(38)-tetraen-30-yl]non-8-enoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Carboxymycobactin S

# HET_ID:
CM1

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C36H52N5O12.Fe/c1-24(22-30(43)37-26-15-10-13-21-41(51)35(26)48)53-36(49)27(38-33(47)28-23-52-34(39-28)25-14-8-9-17-29(25)42)16-11-12-20-40(50)31(44)18-6-4-2-3-5-7-19-32(45)46;/h6,8-9,14,17-18,24,26-28,30-31,37,42-43H,2-5,7,10-13,15-16,19-23H2,1H3,(H,38,47)(H,45,46);/q-3;+4/p-1/b18-6+;/t24-,26+,27-,28+,30-,31-;/m0./s1

# InChI_Key:
InChIKey=FHVPNAZTTVYYAS-JSXYRWHJSA-M

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1926

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
801.661

# Molecular_Weight_Mono:
801.288364254

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1X89

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
2.64

# Predicted_LogS:
-3.9

# Predicted_Water_Solubility:
1.03e-01 g/l

# Primary_Accession_No:
DB01926

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936260

# PubChem_Substance_ID:
46507901

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00951

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
C[C@H]1C[C@H](O)N[C@@H]2CCCCN(O[Fe@@]34O[C@@H](\C=C\CCCCCCC(O)=O)[N@](CCCC[C@H](NC(=O)[C@H]5COC(=N5)C5=CC=CC=C5O3)C(=O)O1)O4)C2=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:37 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Secreted protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
LCN2

# Drug_Target_1_GenBank_ID_Gene:
X83006

# Drug_Target_1_GenBank_ID_Protein:
929657

# Drug_Target_1_GeneCard_ID:
LCN2

# Drug_Target_1_Gene_Name:
LCN2

# Drug_Target_1_Gene_Sequence:
>597 bp
ATGCCCCTAGGTCTCCTGTGGCTGGGCCTAGCCCTGTTGGGGGCTCTGCATGCCCAGGCC
CAGGACTCCACCTCAGACCTGATCCCAGCCCCACCTCTGAGCAAGGTCCCTCTGCAGCAG
AACTTCCAGGACAACCAATTCCAGGGGAAGTGGTATGTGGTAGGCCTGGCAGGGAATGCA
ATTCTCAGAGAAGACAAAGACCCGCAAAAGATGTATGCCACCATCTATGAGCTGAAAGAA
GACAAGAGCTACAATGTCACCTCCGTCCTGTTTAGGAAAAAGAAGTGTGACTACTGGATC
AGGACTTTTGTTCCAGGTTGCCAGCCCGGCGAGTTCACGCTGGGCAACATTAAGAGTTAC
CCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAACCAGCATGCTATG
GTGTTCTTTAAGAAAGTTTCTCAAAACAGGGAGTACTTCAAGATCACCCTCTACGGGAGA
ACCAAGGAGCTGACTTCGGAACTAAAGGAGAACTTCATCCGCTTCTCCAAATCTCTGGGC
CTCCCTGAAAACCACATCGTCTTCCCTGTCCCAATCGACCAGTGTATCGACGGCTGA

# Drug_Target_1_General_Function:
Involved in lipophilic molecule transport

# Drug_Target_1_General_References:
10339412	Coles M, Diercks T, Muehlenweg B, Bartsch S, Zolzer V, Tschesche H, Kessler H: The solution structure and dynamics of human neutrophil gelatinase-associated lipocalin. J Mol Biol. 1999 May 28;289(1):139-57.
10684642	Goetz DH, Willie ST, Armen RS, Bratt T, Borregaard N, Strong RK: Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry. 2000 Feb 29;39(8):1935-41.
1281792	Triebel S, Blaser J, Reinke H, Tschesche H: A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett. 1992 Dec 21;314(3):386-8.
7683678	Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N: Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993 May 15;268(14):10425-32.
7835423	Bartsch S, Tschesche H: Cloning and expression of human neutrophil lipocalin cDNA derived from bone marrow and ovarian cancer cells. FEBS Lett. 1995 Jan 9;357(3):255-9.
8060329	Bundgaard JR, Sengelov H, Borregaard N, Kjeldsen L: Molecular cloning and expression of a cDNA encoding NGAL: a lipocalin expressed in human neutrophils. Biochem Biophys Res Commun. 1994 Aug 15;202(3):1468-75.

# Drug_Target_1_HGNC_ID:
HGNC:6526

# Drug_Target_1_HPRD_ID:
02551

# Drug_Target_1_ID:
1782

# Drug_Target_1_Locus:
9q34

# Drug_Target_1_Molecular_Weight:
22588

# Drug_Target_1_Name:
Neutrophil gelatinase-associated lipocalin

# Drug_Target_1_Number_of_Residues:
198

# Drug_Target_1_PDB_ID:
1NGL

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00061	Lipocalin

# Drug_Target_1_Protein_Sequence:
>Neutrophil gelatinase-associated lipocalin precursor
MPLGLLWLGLALLGALHAQAQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNA
ILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGCQPGEFTLGNIKSY
PGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLG
LPENHIVFPVPIDQCIDG

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-20

# Drug_Target_1_Specific_Function:
Transport of small lipophilic substances (Potential)

# Drug_Target_1_SwissProt_ID:
P80188

# Drug_Target_1_SwissProt_Name:
NGAL_HUMAN

# Drug_Target_1_Synonyms:
25 kDa alpha-2-microglobulin-related subunit of MMP-9
Lipocalin-2
NGAL
Neutrophil gelatinase-associated lipocalin precursor
Oncogene 24p3
p25

# Drug_Target_1_Theoretical_pI:
9.24

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01926
